Clinical trials: Neoplasms, Solid Tumor
Esophageal Neoplasms
The Predictive Value of CT-PET in Esophageal Cancer
A major focus of research in oncology is to identify patients who, following induction therapy, have a complete pathologic response, presenting opportunities for novel trials, including extended therapy or non-operative…
- Trial name
- NCT02385604
- Where
- Ireland
- Volunteers
- 250 people
- Sponsor
- St. James's Hospital, Ireland
Advanced Solid Tumors, Lymphoma
Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss
This study will evaluate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of AG-270 in participants with advanced solid tumors or lymphoma with homozygous MTAP deletion.
- Trial name
- NCT03435250
- Testing
- AG-270, docetaxel, nab-paclitaxel
- Where
- 8 sites in United States, France and 1 more
- Volunteers
- 123 people
- Sponsor
- Institut de Recherches Internationales Servier
Neoplasms, Lymphomas
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
Background: Belinostat is an experimental cancer treatment drug that works by helping to turn on genes that limit cell growth and survival of cancer cells. These genes are often switched off in tumors.
- Trial name
- NCT01273155
- Testing
- Belinostat
- Where
- 7 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Cancer (Solid Tumors), Vomiting
Steroid Sparing Regimen With Olanzapine and Palonosetron for Emetic Prevention for High Dose Cisplatin
A phase II study evaluating dexamethasone sparing regimen with olanzapine and palonosetron for patients receiving high dose cisplatin to prevent chemotherapy induced nausea and vomiting
- Conditions
- Cancer (Solid Tumors), Vomiting, Cisplatin, Olanzapine
- Trial name
- NCT07699276
- Testing
- dexamethasone sparing
- Where
- Thailand
- Volunteers
- 95 people
- Sponsor
- Mahidol University
Cancer, Tumors
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
The purpose of this study is to investigate BMS-986226 administered alone or in combination with nivolumab or ipilimumab.
- Conditions
- Cancer, Tumors, Neoplasm, Malignancy
- Trial name
- NCT03251924
- Testing
- BMS-986226, Nivolumab, Ipilimumab
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 80 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumors
Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment
This study provides a mechanism for continued administration of ALN-VSP02 therapy to patients with cancer who completed participation in another ALN-VSP02 clinical study.
- Trial name
- NCT01158079
- Testing
- ALN-VSP02
- Where
- 10 sites in United States, Spain
- Volunteers
- 7 people
- Sponsor
- Alnylam Pharmaceuticals
Advanced Solid Tumor, Non Small Cell Lung Cancer
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
A Phase 1b/2, open-label, multicenter study to determine the recommended phase 2 (RP2D) of ABT-101in solid tumor and to explore antitumor activities of ABT-101 in patients with HER 2 mutated non-small cell lung cancer (NSCLC)
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer, HER2 Mutations
- Trial name
- NCT05532696
- Testing
- ABT-101
- Where
- 5 sites in Taiwan
- Volunteers
- 61 people
- Sponsor
- Anbogen Therapeutics, Inc.
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers
This study evaluates relationships among physical activity, thinking, and memory after cancer treatment in survivors of adolescent and young adult cancers.
- Trial name
- IMPACT (NCT06880861)
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Mayo Clinic
mCRPC or Advanced/Metastatic Solid Tumors
A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours
This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX3902 in patients with mCRPC and other advanced solid tumours.
- Trial name
- NCT07533708
- Testing
- HLX3902
- Where
- 5 sites in China
- Volunteers
- 48 people
- Sponsor
- Shanghai Henlius Biotech
Solid Tumor, Adult
Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC
1. To demonstrate the ability to detect specific cancer mutations in ctDNA isolated from plasma of stage IV cancer patients at HCC. 2.
- Trial name
- NCT03302325
- Testing
- research blood draws
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical University of South Carolina
Advanced Solid Tumors
A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors
This is a single-arm, open-label, multi-center phase 1 clinical study designed to evaluate the safety and preliminary efficacy of NK042 cell injection in patients with advanced solid tumors.
- Trial name
- NKSOLID (NCT06773091)
- Testing
- NK042, Fludarabine (FLU), Cyclophosphamide (CTX)
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Shanghai NK Cell Technology Co., LTD
Advanced Solid Tumor, Breast Cancer
A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer
The study will evaluate the pharmacokinetics (PK) and safety of a single intravenous (IV) dose of 0.3 mg/kg MB1707 in patients with advanced cancers.
- Conditions
- Advanced Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer, Ovary Cancer
- Trial name
- NCT05465590
- Testing
- MB1707
- Sponsor
- Mainline Biosciences, Inc.
Esophageal Carcinoma, Lung Carcinoma
Yoga Program for Improving the Quality of Life in Couples Coping With Cancer
This clinical trial seeks to learn if a yoga program can improve physical performance, quality of life and symptom burden in cancer patients who are undergoing radiation therapy, and their partners.
- Conditions
- Esophageal Carcinoma, Lung Carcinoma, Malignant Head and Neck Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04607590
- Testing
- Best Practice, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor, Hematological Malignancy
Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells
The aim of this prospective study is to evaluate the feasibility and efficacy of metoprolol, a beta-1 adrenergic receptor blocker, in the treatment of cytokine release syndrome (CRS) caused by chimeric antigen receptor T (CAR T)…
- Trial name
- NCT04082910
- Testing
- Metoprolol, metoprolol, infliximab, etanercept, tocilizumab and/or other agents
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Neoplasm
Safety Study of Infusion of SGT-53 to Treat Solid Tumors
This is a Phase Ib study as a continuation of the original Phase I protocol. The purpose of this Phase Ib study is to evaluate the safety of a single course of SGT-53 in combination with docetaxel and determine the recommended…
- Trial name
- NCT00470613
- Testing
- SGT-53
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- SynerGene Therapeutics, Inc.
Healthy Volunteers, Cancer Patients
Clinical Study of 68Ga-LNC1007 Injection PET/CT
This study is a single-arm, single-center trial aimed at evaluating the safety, pharmacokinetics, biodistribution and dosimetry of 68Ga-LNC1007 Injection in adult healthy volunteers and solid tumor patients.
- Trial name
- NCT06463782
- Testing
- 68Ga-LNC1007 Injection
- Where
- Singapore
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Yantai LNC Biotechnology Singapore PTE. LTD.
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
ABT-751 in Treating Young Patients With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00036959
- Testing
- ABT-751
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Unspecified Adult Solid Tumor, Protocol Specific
Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors
The purpose of this study is to determine the dose of smac mimetic TL32711 that is safe and tolerated when given with gemcitabine hydrochloride to patients with advanced cancer
- Trial name
- NCT01573780
- Testing
- Smac mimetic TL32711, gemcitabine hydrochloride, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Roswell Park Cancer Institute
Unspecified Adult Solid Tumor, Protocol Specific
A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors
The purpose of this study is to determine the Maximum Tolerated Dose and the Dose-Limiting Toxicity of the drug to further evaluate safety and antitumor activity.
- Trial name
- NCT01631279
- Testing
- PR610
- Where
- 6 sites in United States, New Zealand
- Volunteers
- 33 people
- Sponsor
- Proacta, Incorporated
Epidemic Kaposi's Sarcoma, Recurrent Kaposi's Sarcoma
Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill their tumor cells.
- Trial name
- NCT00019188
- Testing
- interleukin-12
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.